Amber Specialty Pharmacy Announces Expansion of EVUSHELD™ Services

OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces the launch of EVUSHELD™ extended services. The United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis of coronavirus 2019 (COVID-19) in adults and children (12 years and older weighing at least 40 kg).

EVUSHELD™ can be prescribed to people who are not currently infected with SARS-CoV-2 and have not recently been exposed to someone infected with SARS-CoV-2 and

  • Who have a moderate to severe immune deficiency due to a medical condition or receiving immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination Where

  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of serious adverse reaction to one or more COVID-19 vaccines and/or to one or more components of the COVID-19 vaccine.

This may include transplant recipients, as well as oncology and other immunocompromised patients. Amber Specialty Pharmacy’s high-level contact service model is designed to support prescribers, such as transplant programs, oncologists and others, who may have patients who may be prescribed EVUSHELD™. The pharmacy provides comprehensive services from the time of referral through delivery and beyond to ensure the best possible patient outcomes.

Amber Specialty Pharmacy will offer EVUSHELD™ at its 19 locations across the United States. They can also coordinate delivery and nursing care for home administration, if necessary.

“Throughout the pandemic, Amber Specialty Pharmacy has always embraced the opportunity to care for our patients. Through the administration of monoclonal antibodies, we focused on providing solutions when our patients needed them most,” said Kristin Williams, President of Amber Specialty Pharmacy. “Our expanded EVUSHELD™ services represent our continued commitment to caring for our patients, especially those who have not had treatment options that provide an adequate immune response.”

For more information about Amber Specialty Pharmacy services, call (888) 370-1724 or visit www.amberpharmacy.com. Learn more about the pharmacy’s COVID-19 therapy offerings here.

Amber Specialty Pharmacy, a subsidiary of Hy-Vee, Inc., is a pioneer and leader in the specialty pharmacy industry with nearly 25 years of experience providing specialty care to people with complex chronic conditions. Amber Specialty Pharmacy has built an exceptional reputation for providing personalized support and quality clinical care to patients and families. This comprehensive care approach meets the medical, emotional, financial and administrative needs of patients across the United States. Amber Specialty Pharmacy is accredited by the Use Review Accreditation Commission (URAC) and the Healthcare Accreditation Commission (ACHC). Amber Specialty Pharmacy is headquartered in Omaha, Nebraska, with 18 additional locations in the United States and Puerto Rico. Amber Specialty Pharmacy has been named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacies.

Comments are closed.